VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement
Zurich, Switzerland, and Brooklyn, New York, USA – VERAXA Biotech AG and Voyager Acquisition Corp. (NASDAQ: VACH) have announced a definitive business combination agreement. The proposed combination would result in a publicly traded, clinical-stage biopharmaceutical company, VERAXA Biotech AG, focused on next-generation cancer therapies, and is expected to list on NASDAQ under the ticker symbol “VERX.”
VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement Read more »